Your browser doesn't support javascript.
loading
Evaluation of a novel approach to circulating tumor cell isolation for cancer gene panel analysis in patients with breast cancer.
Lee, Soo Jeong; Lee, Cham Han; Choi, Sung Ho; Ahn, Sei Hyun; Son, Byung Ho; Lee, Jong Won; Yu, Jong Han; Kwon, Nak-Jung; Lee, Woo Chung; Yang, Kap-Seok; Lee, Dong Hyoung; Han, Du Yeol; Choi, Mi So; Park, Pyeong-Soo; Lee, Hyun Kyung; Kim, Myoung Shin; Lee, Jinseon; Jeon, Byung Hee.
Afiliação
  • Lee SJ; Cytogen, Inc., Songpa-gu, Seoul 138-961, Republic of Korea.
  • Lee CH; Cytogen, Inc., Songpa-gu, Seoul 138-961, Republic of Korea.
  • Choi SH; Cytogen, Inc., Songpa-gu, Seoul 138-961, Republic of Korea.
  • Ahn SH; Department of Surgery, Asan Medical Center Affiliated to The University of Uslan College of Medicine, Songpa-gu, Seoul 138-736, Republic of Korea.
  • Son BH; Department of Surgery, Asan Medical Center Affiliated to The University of Uslan College of Medicine, Songpa-gu, Seoul 138-736, Republic of Korea.
  • Lee JW; Department of Surgery, Asan Medical Center Affiliated to The University of Uslan College of Medicine, Songpa-gu, Seoul 138-736, Republic of Korea.
  • Yu JH; Department of Surgery, Asan Medical Center Affiliated to The University of Uslan College of Medicine, Songpa-gu, Seoul 138-736, Republic of Korea.
  • Kwon NJ; Macrogen, Inc., Geumcheon-gu, Seoul 08511, Republic of Korea.
  • Lee WC; Macrogen, Inc., Geumcheon-gu, Seoul 08511, Republic of Korea.
  • Yang KS; Macrogen, Inc., Geumcheon-gu, Seoul 08511, Republic of Korea.
  • Lee DH; Cytogen, Inc., Songpa-gu, Seoul 138-961, Republic of Korea.
  • Han DY; Cytogen, Inc., Songpa-gu, Seoul 138-961, Republic of Korea.
  • Choi MS; Cytogen, Inc., Songpa-gu, Seoul 138-961, Republic of Korea.
  • Park PS; Cytogen, Inc., Songpa-gu, Seoul 138-961, Republic of Korea.
  • Lee HK; Cytogen, Inc., Songpa-gu, Seoul 138-961, Republic of Korea.
  • Kim MS; Cytogen, Inc., Songpa-gu, Seoul 138-961, Republic of Korea.
  • Lee J; Cytogen, Inc., Songpa-gu, Seoul 138-961, Republic of Korea.
  • Jeon BH; Cytogen, Inc., Songpa-gu, Seoul 138-961, Republic of Korea.
Oncol Lett ; 13(5): 3025-3031, 2017 May.
Article em En | MEDLINE | ID: mdl-28521409
ABSTRACT
Liquid biopsy isolation of circulating tumor cells (CTCs) allows the genomic analysis of CTCs, which is useful in the determination of personalized cancer therapy. In the present study, CTCs from patients with breast cancer were enriched and successfully analyzed using cancer gene panel analysis. Blood samples from 11 patients with breast cancer were collected and CTCs enriched for using size-based filtration. The enriched CTCs were analyzed using immunofluorescence staining with antibodies directed against epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 45. The genomic DNA of CTCs was extracted, amplified and 50 genes screened for mutations using the Ion AmpliSeq™ Cancer Hotspot Panel v2. EpCAM staining detected CTCs in 10/11 patients and the average CTC count was 3.9 in 5 ml blood. The average purity of enriched CTCs was 14.2±29.4% and the average amount of amplified DNA was 28.6±11.9 µg. Catalogue Of Somatic Mutations In Cancer mutations were detected in the CTCs and included IDH2, TP53, NRAS, IDH1, PDGFRA, HRAS, STK11, EGFR, PTEN, MLH1, PIK3CA, CDKN2A, KIT and SMARCB1. In conclusion, a novel size-based filtration approach for the isolation of CTCs was evaluated and successfully applied for the genomic analysis of CTCs from patients with breast cancer.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article